Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia

NCT00914628 is registered in ClinicalTrials.gov with AGC Biologics S.p.A. as lead sponsor.

NCT NCT00914628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00914628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia
Lead sponsor
AGC Biologics S.p.A.
Phase
Phase 3
Overall status
Terminated
Start date
April 12, 2010
Completion date
November 30, 2019
Enrollment
92 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia (category)